© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Aditya Bardia, MD, MPH discusses the present and prospective clinical applications of ctDNA monitoring informed by promising data presented at the ASCO 2022 Annual Meeting.
August 31st 2022
Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.
A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.
Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.
Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.
Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.
Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.